Model construction and thrombolytic treatment of rat portal vein thrombosis.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Portal Vein*/drug effects ; Venous Thrombosis*/drug therapy ; Disease Models, Animal* ; Urokinase-Type Plasminogen Activator*/metabolism ; Thrombolytic Therapy*/methods; Animals ; Rats ; Male ; Rats, Sprague-Dawley ; Fibrinolytic Agents/pharmacology ; Fibrinolytic Agents/therapeutic use ; Fibrinogen/metabolism ; Fibrin Fibrinogen Degradation Products/metabolism

Objective: To construct a stable rat portal vein thrombosis (PVT) model and explore the time window of urokinase thrombolytic therapy on this basis.
Methods: Constructing a rat PVT model by combining anhydrous ethanol disruption of portal endothelium with stasis of blood flow. Forty-eight rats after PVT modeling were divided into control group and experimental group, with 24 rats in each group. The experimental and control groups were given urokinase treatment and saline tail vein injection, respectively. The two groups of rats were observed and compared for PVT formation at 1, 3 and 5 days after modeling, respectively.
Results: A stable rat PVT model was successfully constructed. No significant differences were found in PVT length, portal vein wet weight, and percentage of luminal occlusion area in the control rats at 1, 3, and 5 days after successful modeling (P > 0.05). Compared with control rats 1 day after modeling, the percentage of non-organized thrombus luminal area was significantly decreased (P < 0.0001), and the percentage of organized thrombus luminal area was significantly increased (P < 0.0001) in the PVTs of control rats at 3 and 5 days after modeling. After thrombolytic treatment with urokinase, plasma fibrinogen (FBG) levels were significantly decreased in the experimental group of rats compared with the control group (P < 0.0001), and plasma D-dimer (D2D) levels were significantly increased in the experimental group of rats compared with the control group (P < 0.0001). In addition, we observed prolongation of prothrombin time (PT) in the experimental group at 1, 3 and 5 days after modeling compared to the control group (P = 0.0001). Compared with the control group, portal vein wet weight and PVT length were significantly decreased in the experimental group of rats at 1 day after modeling (P < 0.05), whereas these differences were not found in the two groups of rats at 3 and 5 days after modeling (P > 0.05). The percentage of non-organized thrombus area in the experimental group was significantly decreased compared with that in the control group at 1, 3, and 5 days after modeling (P < 0.05), whereas there was no significant difference in the percentage of lumen area of organized thrombus between the two groups (P > 0.05).
Conclusion: The method of producing a rat PVT model by destroying the endothelium of the portal vein by anhydrous ethanol combined with blood flow stasis is feasible and reproducible. In addition, the optimal time window for thrombolysis in the treatment of PVT in rats using urokinase is the early stage of thrombosis, when the fibrin content is highest.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Zixiang Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Thromb Haemost. 2019 Mar;119(3):496-499. (PMID: 30616246)
J Hepatol. 2021 Aug;75(2):442-453. (PMID: 33930474)
Brain. 2017 Mar 1;140(3):684-691. (PMID: 28040669)
J Thromb Thrombolysis. 2015 Oct;40(3):294-301. (PMID: 25698403)
J Hepatol. 2016 Jan;64(1):179-202. (PMID: 26516032)
PLoS One. 2014 Nov 13;9(11):e112501. (PMID: 25393320)
Exp Ther Med. 2019 May;17(5):3589-3597. (PMID: 30988741)
J Clin Med. 2022 Oct 30;11(21):. (PMID: 36362663)
World J Gastroenterol. 2017 Nov 7;23(41):7470-7477. (PMID: 29151701)
Hepatology. 2022 Apr;75(4):898-911. (PMID: 34559897)
Acta Biochim Biophys Sin (Shanghai). 2021 Feb 4;53(2):265-268. (PMID: 33382072)
Cell Mol Neurobiol. 2020 Apr;40(3):347-355. (PMID: 31552559)
Arch Med Sci. 2023 Jan 13;19(1):283-287. (PMID: 36817663)
ANZ J Surg. 2020 Dec;90(12):2420-2424. (PMID: 32338419)
Biomed Res Int. 2020 Apr 08;2020:3086906. (PMID: 32351989)
Gastroenterol Rep (Oxf). 2017 May;5(2):148-156. (PMID: 28533912)
Gastroenterology. 2019 May;156(6):1582-1599.e1. (PMID: 30771355)
Front Med (Lausanne). 2023 Apr 26;10:1134801. (PMID: 37181351)
Ann Vasc Surg. 2020 Jul;66:362-369. (PMID: 31931125)
J Intern Med. 2023 Feb;293(2):212-227. (PMID: 36208172)

EC 3.4.21.73 (Urokinase-Type Plasminogen Activator)
0 (Fibrinolytic Agents)
9001-32-5 (Fibrinogen)
0 (Fibrin Fibrinogen Degradation Products)

Date Created: 20240802 Date Completed: 20240802 Latest Revision: 20240804

20240804

PMC11296622

10.1371/journal.pone.0308178

39093899